New collaboration delivers cashless services, as well as access to expedited appointments for outpatient cancer treatment services and independent cancer medical consultation, ens ...
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay ...
"Resolution is an excellent company in a market that will grow so we want to secure its potential," he said. Nippon Life currently owns about 23% of Bermuda-based Resolution Life ... owned by a range ...